Candida bloodstream infection in patients with cancer: A retrospective analysis of an 11-year period

IF 1.5 4区 生物学 Q4 MYCOLOGY
Rodrigo Vázquez-Olvera , Patricia Volkow , Consuelo Velázquez-Acosta , Patricia Cornejo-Juárez
{"title":"Candida bloodstream infection in patients with cancer: A retrospective analysis of an 11-year period","authors":"Rodrigo Vázquez-Olvera ,&nbsp;Patricia Volkow ,&nbsp;Consuelo Velázquez-Acosta ,&nbsp;Patricia Cornejo-Juárez","doi":"10.1016/j.riam.2022.12.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><em>Candida</em> bloodstream infection (CBSI) is a growing problem among patients with cancer.</p></div><div><h3>Aim</h3><p>To describe the main clinical and microbiological characteristics in patients with cancer who suffer CBSI.</p></div><div><h3>Methods</h3><p>We reviewed the clinical and microbiological characteristics of all patients with CBSI diagnosed between January 2010 and December 2020, at a tertiary-care oncological hospital. Analysis was done according to the <em>Candida</em> species found. Multivariate logistic regression analysis was used to determine the risk factors associated with 30-day mortality.</p></div><div><h3>Results</h3><p>There were 147 CBSIs diagnosed, 78 (53%) in patients with hematologic malignancies. The main <em>Candida</em> species identified were <span><em>Candida albicans</em></span> (<em>n</em> <!-->=<!--> <!-->54), <span><em>Candida glabrata</em></span> (<em>n</em> <!-->=<!--> <!-->40) and <span><em>Candida tropicalis</em></span> (<em>n</em> <!-->=<!--> <!-->29). <em>C. tropicalis</em> had been mainly isolated from patients with hematologic malignancies (79.3%) who had received chemotherapy recently (82.8%), and in patients with severe neutropenia (79.3%). Seventy-five (51%) patients died within the first 30 days, and the multivariate analysis showed the following risk factors: severe neutropenia, a Karnofsky Performance Scale score under 70, septic shock, and not receiving appropriate antifungal treatment.</p></div><div><h3>Conclusions</h3><p>Patients with cancer who develop CBSI had a high mortality related with factors associated with their malignancy. Starting an empirical antifungal therapy the soonest is essential to increase the survival in these patients.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Iberoamericana De Micologia","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130140623000025","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Background

Candida bloodstream infection (CBSI) is a growing problem among patients with cancer.

Aim

To describe the main clinical and microbiological characteristics in patients with cancer who suffer CBSI.

Methods

We reviewed the clinical and microbiological characteristics of all patients with CBSI diagnosed between January 2010 and December 2020, at a tertiary-care oncological hospital. Analysis was done according to the Candida species found. Multivariate logistic regression analysis was used to determine the risk factors associated with 30-day mortality.

Results

There were 147 CBSIs diagnosed, 78 (53%) in patients with hematologic malignancies. The main Candida species identified were Candida albicans (n = 54), Candida glabrata (n = 40) and Candida tropicalis (n = 29). C. tropicalis had been mainly isolated from patients with hematologic malignancies (79.3%) who had received chemotherapy recently (82.8%), and in patients with severe neutropenia (79.3%). Seventy-five (51%) patients died within the first 30 days, and the multivariate analysis showed the following risk factors: severe neutropenia, a Karnofsky Performance Scale score under 70, septic shock, and not receiving appropriate antifungal treatment.

Conclusions

Patients with cancer who develop CBSI had a high mortality related with factors associated with their malignancy. Starting an empirical antifungal therapy the soonest is essential to increase the survival in these patients.

癌症患者的念珠菌血流感染:11年的回顾性分析
背景血液念珠菌感染(CBSI)是癌症患者中日益严重的问题。目的描述癌症合并CBSI患者的主要临床和微生物学特征。方法我们回顾了2010年1月至2020年12月在一家三级肿瘤医院诊断的所有CBSI患者的临床和微生物学特征。根据发现的念珠菌种类进行分析。采用多变量逻辑回归分析来确定与30天死亡率相关的危险因素。结果共诊断出147例CBSI,其中78例(53%)为血液系统恶性肿瘤。鉴定的主要念珠菌种类为白色念珠菌(n=54)、光滑念珠菌(n=40)和热带念珠菌(n=29)。热带C.tropicalis主要从最近接受化疗的血液系统恶性肿瘤患者(79.3%)和严重中性粒细胞减少症患者(79.8%)中分离出来。75名(51%)患者在前30天内死亡,多变量分析显示以下风险因素:严重的中性粒细胞减少症、Karnofsky性能量表评分低于70、感染性休克、,以及未接受适当的抗真菌治疗。结论癌症患者发生CBSI的死亡率较高,且与恶性因素相关。尽早开始经验性抗真菌治疗对于提高这些患者的生存率至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
17
审稿时长
81 days
期刊介绍: Revista Iberoamericana de Micología (Ibero-American Journal of Mycology) is the official journal of the Asociación Española de Micología, Asociación Venezolana de Micología and Asociación Argentina de Micología (The Spanish, Venezuelan, and Argentinian Mycology Associations). The Journal gives priority to publishing articles on studies associated with fungi and their pathogenic action on humans and animals, as well as any scientific studies on any aspect of mycology. The Journal also publishes, in Spanish and in English, original articles, reviews, mycology forums, editorials, special articles, notes, and letters to the editor, that have previously gone through a scientific peer review process.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信